BIB vs TBXU
ProShares Ultra NASDAQ Biotechnology against Direxion Daily Biotech Top 5 Bull 2X ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
21%
5 shared positions
Fee gap
3 bp
BIB is cheaper
1-year return gap
0.3 pts
TBXU is ahead
Larger fund
BIB
$102M
Side by side
| BIB | TBXU | |
|---|---|---|
| Fund | ProShares Ultra NASDAQ Biotechnology | Direxion Daily Biotech Top 5 Bull 2X ETF |
| Issuer | ProShares | Direxion |
| Category | Leveraged Equity | Leveraged Equity |
| Expense ratio | 0.95% | 0.98% |
| Assets | $102M | $2.6M |
| Average daily dollar volume | $997K | $66K |
| Listed | Apr 6, 2010 | Sep 30, 2025 |
| FrenzyCap score | 47 | 21 |
| 1-month return | +4.5% | +20.5% |
| 3-month return | +5.7% | +18.6% |
| Year to date | +45.6% | +53.9% |
| 1-year return | +52.7% | +52.9% |
| 30-day volatility | 61.5% | 53.0% |
| Worst drawdown, 1 year | −17.9% | −26.8% |
| Trailing 12-month yield | 0.19% | 1.60% |
| Holdings | 254 | 11 |
| Top 10 weight | 156.9% | 200.0% |
| Look-through P/E | — | 40.9 |
| Holdings vs fair value | +8.4% | +8.0% |
| Holdings above 200-day average | 82% | 100% |
| Net flow, latest 3 reported months | +$1.5M thru Aug 2026 | −$873K thru Jul 2026 |
| 30-day implied volatility | 50.9% | — |
| Holdings as of | as of Nov 13, 2026issuer data | as of Nov 13, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
21% of BIB · 55% of TBXUSector mix of the stock holdings
| Sector | BIB | TBXU | Gap |
|---|---|---|---|
| Health Care | 61.2% | 55.4% | +5.8% |
| Technology | 2.1% | 0.0% | +2.1% |
| Materials | 0.0% | 0.0% | +0.0% |
More: full overlap table · BIB holdings · TBXU holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.